{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T08:12:33Z","timestamp":1791360753022,"version":"4.3.1"},"reference-count":97,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000862","name":"Doris Duke Charitable Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000862","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11883-025-01365-0","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T07:32:30Z","timestamp":1763364750000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Ancestral Variation in Lp(a): Epidemiology, Isoform Diversity, and Testing"],"prefix":"10.1007","volume":"27","author":[{"given":"Priyansh","family":"Shah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Trabanino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shyon","family":"Parsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,17]]},"reference":[{"issue":"39","key":"1365_CR1","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","volume":"43","author":"F Kronenberg","year":"2022","unstructured":"Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European atherosclerosis society consensus statement. Eur Heart J. 2022;43(39):3925\u201346.","journal-title":"Eur Heart J"},{"key":"1365_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.atherosclerosis.2022.04.003","volume":"349","author":"S Coassin","year":"2022","unstructured":"Coassin S, Kronenberg F. Lipoprotein(a) beyond the kringle IV repeat polymorphism: the complexity of genetic variation in the LPA gene. Atherosclerosis. 2022;349:17\u201335.","journal-title":"Atherosclerosis"},{"issue":"7","key":"1365_CR3","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1001\/jamacardio.2022.0987","volume":"7","author":"F Duarte Lau","year":"2022","unstructured":"Duarte Lau F, Giugliano RP. Lipoprotein(a) and its significance in cardiovascular disease: a review. JAMA Cardiol. 2022;7(7):760\u20139.","journal-title":"JAMA Cardiol"},{"key":"1365_CR4","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1001\/jama.2025.2373","volume":"333","author":"S Mora","year":"2025","unstructured":"Mora S, Kronenberg F. Lipoprotein(a). JAMA. 2025;333:1918\u20139.","journal-title":"JAMA"},{"key":"1365_CR5","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1161\/ATV.0000000000000147","volume":"42","author":"G Reyes-Soffer","year":"2022","unstructured":"Reyes-Soffer G, Ginsberg HN, Berglund L, et al. Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2022;42:e48-60.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1365_CR6","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/S0140-6736(24)01308-4","volume":"404","author":"BG Nordestgaard","year":"2024","unstructured":"Nordestgaard BG, Langsted A. Lipoprotein(a) and cardiovascular disease. Lancet. 2024;404:1255\u201364.","journal-title":"Lancet"},{"key":"1365_CR7","first-page":"27","volume":"84","author":"C Bess","year":"2024","unstructured":"Bess C, Mehta A, Joshi PH. All we need to know about lipoprotein(a). Prog Cardiovasc Dis. 2024;84:27\u201333.","journal-title":"Prog Cardiovasc Dis"},{"key":"1365_CR8","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1172\/JCI115855","volume":"90","author":"E Boerwinkle","year":"1992","unstructured":"Boerwinkle E, Leffert CC, Lin J, Lackner C, Chiesa G, Hobbs HH. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest. 1992;90:52\u201360.","journal-title":"J Clin Invest"},{"key":"1365_CR9","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.jacc.2021.05.037","volume":"78","author":"JF Schachtl-Riess","year":"2021","unstructured":"Schachtl-Riess JF, Kheirkhah A, Gr\u00fcneis R, et al. Frequent LPA KIV-2 variants lower lipoprotein(a) concentrations and protect against coronary artery disease. J Am Coll Cardiol. 2021;78:437\u201349.","journal-title":"J Am Coll Cardiol"},{"key":"1365_CR10","doi-asserted-by":"publisher","first-page":"100336","DOI":"10.1016\/j.jlr.2023.100336","volume":"64","author":"A Matveyenko","year":"2023","unstructured":"Matveyenko A, Matienzo N, Ginsberg H, Nandakumar R, Seid H, Ramakrishnan R, et al. Relationship of apolipoprotein(a) isoform size with clearance and production of lipoprotein(a) in a diverse cohort. J Lipid Res. 2023;64:100336.","journal-title":"J Lipid Res"},{"key":"1365_CR11","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/164_2021_504","volume":"270","author":"F Kronenberg","year":"2022","unstructured":"Kronenberg F. Lipoprotein(a). Handb Exp Pharmacol. 2022;270:201\u201332.","journal-title":"Handb Exp Pharmacol"},{"key":"1365_CR12","first-page":"1183","volume":"40","author":"V Higgins","year":"2024","unstructured":"Higgins V, White-Al Habeeb NMA, Bailey D, Beriault DR, Blasutig IM, Collier CP, Venner AA, Adeli K, Canadian Society of Clinical Chemists Working Group on Reference Interval Harmonization. Canadian society of clinical chemists harmonized pediatric lipid reporting recommendations for clinical laboratories. Can J Cardiol. 2024;40:1183\u201397.","journal-title":"Can J Cardiol"},{"key":"1365_CR13","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1016\/j.jacl.2018.07.003","volume":"12","author":"S Tsimikas","year":"2018","unstructured":"Tsimikas S, Fazio S, Viney NJ, Xia S, Witztum JL, Marcovina SM. Relationship of lipoprotein(a) molar concentrations and mass according to lipoprotein(a) thresholds and apolipoprotein(a) isoform size. J Clin Lipidol. 2018;12:1313\u201323.","journal-title":"J Clin Lipidol"},{"key":"1365_CR14","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1161\/ATVBAHA.120.315291","volume":"41","author":"AP Patel","year":"2021","unstructured":"Patel AP, Wang (\u6c6a\u654f\u5148) M, Pirruccello JP, Ellinor PT, Ng K, Kathiresan S, Khera AV. Lp(a) (Lipoprotein[a]) concentrations and incident atherosclerotic cardiovascular disease: new insights from a large National biobank. Arterioscler Thromb Vasc Biol. 2021;41:465\u201374.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1365_CR15","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1001\/jamacardio.2020.5398","volume":"6","author":"M Trinder","year":"2021","unstructured":"Trinder M, Uddin MM, Finneran P, Aragam KG, Natarajan P. Clinical utility of Lipoprotein(a) and LPA genetic risk score in risk prediction of incident atherosclerotic cardiovascular disease. JAMA Cardiol. 2021;6:287\u201395.","journal-title":"JAMA Cardiol"},{"key":"1365_CR16","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.jacc.2022.06.019","volume":"80","author":"S Tsimikas","year":"2022","unstructured":"Tsimikas S, Marcovina SM. Ancestry, lipoprotein(a), and cardiovascular risk thresholds: JACC review topic of the week. J Am Coll Cardiol. 2022;80:934\u201346.","journal-title":"J Am Coll Cardiol"},{"key":"1365_CR17","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.atherosclerosis.2022.04.005","volume":"349","author":"A Mehta","year":"2022","unstructured":"Mehta A, Jain V, Saeed A, Saseen JJ, Gulati M, Ballantyne CM, et al. Lipoprotein(a) and ethnicities. Atherosclerosis. 2022;349:42\u201352.","journal-title":"Atherosclerosis"},{"key":"1365_CR18","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1001\/jamacardio.2023.1134","volume":"8","author":"PH Joshi","year":"2023","unstructured":"Joshi PH, Marcovina S, Orroth K, et al. Heterogeneity of lipoprotein(a) levels among Hispanic or Latino individuals residing in the US. JAMA Cardiol. 2023;8:691\u20136.","journal-title":"JAMA Cardiol"},{"key":"1365_CR19","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1097\/MOL.0000000000000753","volume":"32","author":"G Reyes-Soffer","year":"2021","unstructured":"Reyes-Soffer G. The impact of race and ethnicity on lipoprotein(a) levels and cardiovascular risk. Curr Opin Lipidol. 2021;32:163\u20136.","journal-title":"Curr Opin Lipidol"},{"key":"1365_CR20","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1161\/CIRCULATIONAHA.118.034311","volume":"139","author":"G Par\u00e9","year":"2019","unstructured":"Par\u00e9 G, \u00c7aku A, McQueen M, et al. Lipoprotein(a) levels and the risk of myocardial infarction among 7 ethnic groups. Circulation. 2019;139:1472\u201382.","journal-title":"Circulation"},{"key":"1365_CR21","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1001\/jamacardio.2025.1603","volume":"10","author":"HS Bhatia","year":"2025","unstructured":"Bhatia HS, Ambrosio M, Razavi AC, et al. AHA PREVENT equations and Lipoprotein(a) for cardiovascular disease risk: insights from MESA and the UK biobank. JAMA Cardiol. 2025;10:810\u20138.","journal-title":"JAMA Cardiol"},{"key":"1365_CR22","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1038\/s41467-018-04668-w","volume":"9","author":"SM Zekavat","year":"2018","unstructured":"Zekavat SM, Ruotsalainen S, Handsaker RE, et al. Deep coverage whole genome sequences and plasma lipoprotein(a) in individuals of European and African ancestries. Nat Commun. 2018;9:2606.","journal-title":"Nat Commun"},{"key":"1365_CR23","doi-asserted-by":"publisher","first-page":"e14581","DOI":"10.1371\/journal.pone.0014581","volume":"6","author":"RC Deo","year":"2011","unstructured":"Deo RC, Wilson JG, Xing C, et al. Single-nucleotide polymorphisms in LPA explain most of the ancestry-specific variation in Lp(a) levels in African Americans. PLoS One. 2011;6:e14581.","journal-title":"PLoS One"},{"issue":"19","key":"1365_CR24","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1161\/CIR.0000000000001139","volume":"147","author":"LS Mehta","year":"2023","unstructured":"Mehta LS, Velarde GP, Lewey J, et al. Cardiovascular disease risk factors in women: the impact of race and ethnicity: a scientific statement from the American Heart Association. Circulation. 2023;147(19):1471\u201387.","journal-title":"Circulation"},{"key":"1365_CR25","doi-asserted-by":"publisher","first-page":"e033654","DOI":"10.1161\/JAHA.123.033654","volume":"13","author":"AS Volgman","year":"2024","unstructured":"Volgman AS, Koschinsky ML, Mehta A, Rosenson RS. Genetics and pathophysiological mechanisms of lipoprotein(a)-associated cardiovascular risk. J Am Heart Assoc. 2024;13:e033654.","journal-title":"J Am Heart Assoc"},{"key":"1365_CR26","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1161\/CIR.0000000000000580","volume":"138","author":"AS Volgman","year":"2018","unstructured":"Volgman AS, Palaniappan LS, Aggarwal NT, et al. Atherosclerotic cardiovascular disease in South Asians in the United States: epidemiology, risk factors, and treatments: a scientific statement from the American Heart Association. Circulation. 2018;138:e1-34.","journal-title":"Circulation"},{"key":"1365_CR27","doi-asserted-by":"publisher","unstructured":"Tsioulos G, Kounatidis D, Vallianou NG, Poulaki A, Kotsi E, Christodoulatos GS, et al. Lipoprotein(a) and atherosclerotic cardiovascular disease: where do we stand? Int J Mol Sci. 2024. https:\/\/doi.org\/10.3390\/ijms25063537.","DOI":"10.3390\/ijms25063537"},{"key":"1365_CR28","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1161\/CIRCULATIONAHA.116.024611","volume":"135","author":"S-R Lee","year":"2017","unstructured":"Lee S-R, Prasad A, Choi Y-S, Xing C, Clopton P, Witztum JL, et al. LPA gene, ethnicity, and cardiovascular events. Circulation. 2017;135:251\u201363.","journal-title":"Circulation"},{"key":"1365_CR29","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1080\/10408363.2023.2229915","volume":"60","author":"SM Marcovina","year":"2023","unstructured":"Marcovina SM. Lipoprotein(a): a genetically determined risk factor for cardiovascular disease. Crit Rev Clin Lab Sci. 2023;60:560\u201372.","journal-title":"Crit Rev Clin Lab Sci"},{"key":"1365_CR30","doi-asserted-by":"publisher","first-page":"e011781","DOI":"10.1161\/JAHA.118.011781","volume":"8","author":"DC Chan","year":"2019","unstructured":"Chan DC, Watts GF, Coll B, Wasserman SM, Marcovina SM, Barrett PHR. Lipoprotein(a) particle production as a determinant of plasma lipoprotein(a) concentration across varying apolipoprotein(a) isoform sizes and background cholesterol-lowering therapy. J Am Heart Assoc. 2019;8:e011781.","journal-title":"J Am Heart Assoc"},{"key":"1365_CR31","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1161\/01.ATV.0000144010.55563.63","volume":"24","author":"L Berglund","year":"2004","unstructured":"Berglund L, Ramakrishnan R. Lipoprotein(a): an elusive cardiovascular risk factor. Arterioscler Thromb Vasc Biol. 2004;24:2219\u201326.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1365_CR32","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","volume":"361","author":"R Clarke","year":"2009","unstructured":"Clarke R, Peden JF, Hopewell JC, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med. 2009;361:2518\u201328.","journal-title":"N Engl J Med"},{"key":"1365_CR33","doi-asserted-by":"publisher","first-page":"2390","DOI":"10.1093\/hmg\/ddu731","volume":"24","author":"W Lu","year":"2015","unstructured":"Lu W, Cheng Y-C, Chen K, et al. Evidence for several independent genetic variants affecting lipoprotein (a) cholesterol levels. Hum Mol Genet. 2015;24:2390\u2013400.","journal-title":"Hum Mol Genet"},{"key":"1365_CR34","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1161\/STROKEAHA.110.591230","volume":"42","author":"J Ronald","year":"2011","unstructured":"Ronald J, Rajagopalan R, Cerrato F, Nord AS, Hatsukami T, Kohler T, et al. Genetic variation in LPAL2, LPA, and PLG predicts plasma lipoprotein(a) level and carotid artery disease risk. Stroke. 2011;42:2\u20139.","journal-title":"Stroke"},{"key":"1365_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25020736","author":"S Ugov\u0161ek","year":"2024","unstructured":"Ugov\u0161ek S, Rehberger Likozar A, Levstek T, Trebu\u0161ak Podkraj\u0161ek K, Zupan J, \u0160ebe\u0161tjen M. Haplotype of the lipoprotein(a) gene variants rs10455872 and rs3798220 is associated with parameters of coagulation, fibrinolysis, and inflammation in patients after myocardial infarction and highly elevated lipoprotein(a) values. Int J Mol Sci. 2024. https:\/\/doi.org\/10.3390\/ijms25020736.","journal-title":"Int J Mol Sci"},{"key":"1365_CR36","unstructured":"rs3798220. https:\/\/www.snpedia.com\/index.php\/Rs3798220. Accessed 18 Sep 2025."},{"key":"1365_CR37","unstructured":"rs10455872. https:\/\/www.snpedia.com\/index.php\/Rs10455872. Accessed 18 Sep 2025."},{"key":"1365_CR38","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1089\/met.2011.0026","volume":"9","author":"B Enkhmaa","year":"2011","unstructured":"Enkhmaa B, Anuurad E, Zhang W, Tran T, Berglund L. Lipoprotein(a): genotype-phenotype relationship and impact on atherogenic risk. Metab Syndr Relat Disord. 2011;9:411\u20138.","journal-title":"Metab Syndr Relat Disord"},{"key":"1365_CR39","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.116.308011","author":"S Varvel","year":"2016","unstructured":"Varvel S, McConnell JP, Tsimikas S. Prevalence of elevated Lp(a) mass levels and patient thresholds in 532 359 patients in the United States. Arterioscler Thromb Vasc Biol. 2016. https:\/\/doi.org\/10.1161\/ATVBAHA.116.308011.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1365_CR40","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1194\/jlr.P091249","volume":"60","author":"B Enkhmaa","year":"2019","unstructured":"Enkhmaa B, Anuurad E, Zhang W, Kim K, Berglund L. Heritability of apolipoprotein (a) traits in two-generational African-American and Caucasian families. J Lipid Res. 2019;60:1603\u20139.","journal-title":"J Lipid Res"},{"key":"1365_CR41","doi-asserted-by":"crossref","unstructured":"(2019) A genome-wide association study on lipoprotein (a) levels and coronary artery disease severity in a Chinese population. J Lipid Res 60:1440\u20138.","DOI":"10.1194\/jlr.P091009"},{"key":"1365_CR42","unstructured":"rs9457951. https:\/\/www.snpedia.com\/index.php\/Rs9457951. Accessed 18 Sep 2025."},{"key":"1365_CR43","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1093\/eurheartj\/ehr350","volume":"33","author":"Q Qi","year":"2012","unstructured":"Qi Q, Workalemahu T, Zhang C, Hu FB, Qi L. Genetic variants, plasma lipoprotein(a) levels, and risk of cardiovascular morbidity and mortality among two prospective cohorts of type 2 diabetes. Eur Heart J. 2012;33:325\u201334.","journal-title":"Eur Heart J"},{"key":"1365_CR44","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s11883-022-01016-8","volume":"24","author":"K Chemello","year":"2022","unstructured":"Chemello K, Blom DJ, Marais AD, Lambert G, Blanchard V. Genetic and mechanistic insights into the modulation of circulating lipoprotein (a) concentration by Apolipoprotein E isoforms. Curr Atheroscler Rep. 2022;24:399\u2013405.","journal-title":"Curr Atheroscler Rep"},{"key":"1365_CR45","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1161\/ATVBAHA.120.314965","volume":"41","author":"M Hoekstra","year":"2021","unstructured":"Hoekstra M, Chen HY, Rong J, et al. Genome-Wide association study highlights as a novel locus for Lipoprotein(a) Levels-Brief report. Arterioscler Thromb Vasc Biol. 2021;41:458\u201364.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1365_CR46","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1161\/01.ATV.18.12.1870","volume":"18","author":"A Gaw","year":"1998","unstructured":"Gaw A, Brown EA, Ford I. Impact of apo(a) length polymorphism and the control of plasma Lp(a) concentrations: evidence for a threshold effect. Arterioscler Thromb Vasc Biol. 1998;18:1870\u20136.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1365_CR47","doi-asserted-by":"publisher","first-page":"174","DOI":"10.12997\/jla.2025.14.2.174","volume":"14","author":"JA Kim","year":"2025","unstructured":"Kim JA, Kim NH. Lipoprotein(a) and cardiovascular risk in Asian populations: a comprehensive review. J Lipid Atheroscler. 2025;14:174\u201387.","journal-title":"J Lipid Atheroscler"},{"key":"1365_CR48","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1016\/j.jacc.2019.10.019","volume":"74","author":"DF Gudbjartsson","year":"2019","unstructured":"Gudbjartsson DF, Thorgeirsson G, Sulem P, et al. Lipoprotein(a) concentration and risks of cardiovascular disease and diabetes. J Am Coll Cardiol. 2019;74:2982\u201394.","journal-title":"J Am Coll Cardiol"},{"key":"1365_CR49","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.atherosclerosis.2018.06.863","volume":"275","author":"EM Ooi","year":"2018","unstructured":"Ooi EM, Ellis KL, Barrett PHR, Watts GF, Hung J, Beilby JP, et al. Lipoprotein(a) and apolipoprotein(a) isoform size: associations with angiographic extent and severity of coronary artery disease, and carotid artery plaque. Atherosclerosis. 2018;275:232\u20138.","journal-title":"Atherosclerosis"},{"key":"1365_CR50","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1111\/joim.12187","volume":"276","author":"JC Hopewell","year":"2014","unstructured":"Hopewell JC, Seedorf U, Farrall M, et al. Impact of lipoprotein(a) levels and apolipoprotein(a) isoform size on risk of coronary heart disease. J Intern Med. 2014;276:260\u20138.","journal-title":"J Intern Med"},{"key":"1365_CR51","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.atherosclerosis.2022.04.001","volume":"349","author":"ML Koschinsky","year":"2022","unstructured":"Koschinsky ML, Boffa MB. Oxidized phospholipid modification of lipoprotein(a): epidemiology, biochemistry and pathophysiology. Atherosclerosis. 2022;349:92\u2013100.","journal-title":"Atherosclerosis"},{"key":"1365_CR52","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1161\/CIRCULATIONAHA.108.836940","volume":"119","author":"S Tsimikas","year":"2009","unstructured":"Tsimikas S, Clopton P, Brilakis ES, Marcovina SM, Khera A, Miller ER, et al. Relationship of oxidized phospholipids on Apolipoprotein B-100 particles to race\/ethnicity, Apolipoprotein(a) isoform size, and cardiovascular risk factors: results from the Dallas heart study. Circulation. 2009;119:1711\u20139.","journal-title":"Circulation"},{"key":"1365_CR53","doi-asserted-by":"publisher","first-page":"e020158","DOI":"10.1161\/JAHA.120.020158","volume":"10","author":"L Berglund","year":"2021","unstructured":"Berglund L, Kim K, Zhang W, Prakash N, Truax K, Anuurad E, et al. Lp(a)-associated oxidized phospholipids in healthy black and white participants in relation to apo(a) size, age, and family structure. J Am Heart Assoc. 2021;10:e020158.","journal-title":"J Am Heart Assoc"},{"key":"1365_CR54","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/s41569-018-0153-2","volume":"16","author":"MB Boffa","year":"2019","unstructured":"Boffa MB, Koschinsky ML. Oxidized phospholipids as a unifying theory for lipoprotein(a) and cardiovascular disease. Nat Rev Cardiol. 2019;16:305\u201318.","journal-title":"Nat Rev Cardiol"},{"key":"1365_CR55","doi-asserted-by":"publisher","first-page":"e16604","DOI":"10.1371\/journal.pone.0016604","volume":"6","author":"L Dumitrescu","year":"2011","unstructured":"Dumitrescu L, Glenn K, Brown-Gentry K, Shephard C, Wong M, Rieder MJ, et al. Variation in LPA is associated with Lp(a) levels in three populations from the third National health and nutrition examination survey. PLoS One. 2011;6:e16604.","journal-title":"PLoS One"},{"key":"1365_CR56","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1093\/eurheartj\/ehad055","volume":"44","author":"PE Thomas","year":"2023","unstructured":"Thomas PE, Vedel-Krogh S, Kamstrup PR, Nordestgaard BG. Lipoprotein(a) is linked to atherothrombosis and aortic valve stenosis independent of C-reactive protein. Eur Heart J. 2023;44:1449\u201360.","journal-title":"Eur Heart J"},{"key":"1365_CR57","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1161\/CIRCULATIONAHA.124.072086","volume":"151","author":"R Clarke","year":"2025","unstructured":"Clarke R, Wright N, Lin K, et al. Causal relevance of Lp(a) for coronary heart disease and stroke types in East Asian and European ancestry populations: a Mendelian randomization study. Circulation. 2025;151:1699\u2013711.","journal-title":"Circulation"},{"key":"1365_CR58","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1001\/jama.2009.1063","volume":"302","author":"S Erqou","year":"2009","unstructured":"Emerging Risk Factors Collaboration, Erqou S, Kaptoge S, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA. 2009;302:412\u201323.","journal-title":"JAMA"},{"key":"1365_CR59","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaf297","author":"DE MacDougall","year":"2025","unstructured":"MacDougall DE, Tybj\u00e6rg-Hansen A, Knowles JW, Stern TP, Hartsuff BK, McGowan MP, Baum SJ, Wilemon KA, Nordestgaard BG. Lipoprotein(a) and recurrent atherosclerotic cardiovascular events: the US family heart database. Eur Heart J. 2025. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf297.","journal-title":"Eur Heart J"},{"key":"1365_CR60","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ihj.2019.03.004","volume":"71","author":"EA Enas","year":"2019","unstructured":"Enas EA, Varkey B, Dharmarajan TS, Pare G, Bahl VK. Lipoprotein(a): an independent, genetic, and causal factor for cardiovascular disease and acute myocardial infarction. Indian Heart J. 2019;71:99.","journal-title":"Indian Heart J"},{"key":"1365_CR61","doi-asserted-by":"publisher","first-page":"e77","DOI":"10.1016\/j.jacl.2022.08.007","volume":"16","author":"DP Wilson","year":"2022","unstructured":"Wilson DP, Jacobson TA, Jones PH, Koschinsky ML, McNeal CJ, Nordestgaard BG, et al. Use of lipoprotein(a) in clinical practice: a biomarker whose time has come. A scientific statement from the National lipid association. J Clin Lipidol. 2022;16:e77-95.","journal-title":"J Clin Lipidol"},{"key":"1365_CR62","doi-asserted-by":"publisher","first-page":"1178079","DOI":"10.3389\/fnagi.2023.1178079","volume":"15","author":"Y Huang","year":"2023","unstructured":"Huang Y, Zhang R, Han L, Wu Y, Deng X, Xu T, et al. Lipoprotein(a) and stroke: a two-sample Mendelian randomization study. Front Aging Neurosci. 2023;15:1178079.","journal-title":"Front Aging Neurosci"},{"key":"1365_CR63","doi-asserted-by":"publisher","first-page":"e003354","DOI":"10.1161\/CIRCGEN.120.003354","volume":"14","author":"BA Satterfield","year":"2021","unstructured":"Satterfield BA, Dikilitas O, Safarova MS, et al. Associations of genetically predicted Lp(a) (lipoprotein [a]) levels with cardiovascular traits in individuals of European and African ancestry. Circ Genom Precis Med. 2021;14:e003354.","journal-title":"Circ Genom Precis Med"},{"key":"1365_CR64","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/s40001-022-00825-6","volume":"27","author":"S Wang","year":"2022","unstructured":"Wang S, Zha L, Chen J, Du D, Liu D, Zhong M, et al. The relationship between lipoprotein(a) and risk of cardiovascular disease: a Mendelian randomization analysis. Eur J Med Res. 2022;27:211.","journal-title":"Eur J Med Res"},{"key":"1365_CR65","doi-asserted-by":"publisher","first-page":"3532","DOI":"10.1161\/STROKEAHA.119.026872","volume":"50","author":"Y Pan","year":"2019","unstructured":"Pan Y, Li H, Wang Y, Meng X, Wang Y. Causal effect of Lp(a) [lipoprotein(a)] level on ischemic stroke and Alzheimer disease: a Mendelian randomization study. Stroke. 2019;50:3532\u20139.","journal-title":"Stroke"},{"key":"1365_CR66","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14092990","author":"E Panagiotopoulos","year":"2025","unstructured":"Panagiotopoulos E, Palaiodimou L, Theodorou A, et al. Lipoprotein(a) as a stroke biomarker: pathophysiological pathways and therapeutic implications. J Clin Med. 2025. https:\/\/doi.org\/10.3390\/jcm14092990.","journal-title":"J Clin Med"},{"key":"1365_CR67","doi-asserted-by":"publisher","first-page":"3633","DOI":"10.57187\/s.3633","volume":"154","author":"S Rudin","year":"2024","unstructured":"Rudin S, Kriemler L, Dittrich TD, et al. Lipoprotein(a) as a blood marker for large artery atherosclerosis stroke etiology: validation in a prospective cohort from a Swiss stroke center. Swiss Med Wkly. 2024;154:3633.","journal-title":"Swiss Med Wkly"},{"key":"1365_CR68","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1212\/WNL.58.4.653","volume":"58","author":"P Cerrato","year":"2002","unstructured":"Cerrato P, Imperiale D, Fornengo P, Bruno G, Cassader M, Maffeis P, et al. Higher lipoprotein (a) levels in atherothrombotic than lacunar ischemic cerebrovascular disease. Neurology. 2002;58:653\u20135.","journal-title":"Neurology"},{"key":"1365_CR69","doi-asserted-by":"crossref","first-page":"e873","DOI":"10.1161\/CIRCULATIONAHA.105.621086","volume":"113","author":"LB Goldstein","year":"2006","unstructured":"Goldstein LB, Adams R, Alberts MJ, et al. Primary prevention of ischemic stroke: A guideline from the American heart Association\/American stroke association stroke council: cosponsored by the atherosclerotic peripheral vascular disease interdisciplinary working group; cardiovascular nursing council; clinical cardiology council; Nutrition, physical activity, and metabolism council; and the quality of care and outcomes research interdisciplinary working group. Circulation. 2006;113:e873\u2013923.","journal-title":"Circulation"},{"key":"1365_CR70","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1093\/eurheartj\/ehab081","volume":"42","author":"M Arnold","year":"2021","unstructured":"Arnold M, Schweizer J, Nakas CT, et al. Lipoprotein(a) is associated with large artery atherosclerosis stroke aetiology and stroke recurrence among patients below the age of 60 years: results from the BIOSIGNAL study. Eur Heart J. 2021;42:2186\u201396.","journal-title":"Eur Heart J"},{"key":"1365_CR71","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.jacc.2013.09.038","volume":"63","author":"PR Kamstrup","year":"2014","unstructured":"Kamstrup PR, Tybj\u00e6rg-Hansen A, Nordestgaard BG. Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. J Am Coll Cardiol. 2014;63:470\u20137.","journal-title":"J Am Coll Cardiol"},{"key":"1365_CR72","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.atherosclerosis.2021.11.029","volume":"349","author":"M Kaltoft","year":"2022","unstructured":"Kaltoft M, Sigvardsen PE, Afzal S, Langsted A, Fuchs A, K\u00fchl JT, et al. Elevated lipoprotein(a) in mitral and aortic valve calcification and disease: the Copenhagen general population study. Atherosclerosis. 2022;349:166\u201374.","journal-title":"Atherosclerosis"},{"key":"1365_CR73","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1093\/cvr\/cvad062","volume":"119","author":"P Pantelidis","year":"2023","unstructured":"Pantelidis P, Oikonomou E, Lampsas S, et al. Lipoprotein(a) and calcific aortic valve disease initiation and progression: a systematic review and meta-analysis. Cardiovasc Res. 2023;119:1641\u201355.","journal-title":"Cardiovasc Res"},{"key":"1365_CR74","first-page":"77","volume":"27","author":"NSR Lan","year":"2024","unstructured":"Lan NSR, Khan Z, Watts GF. Lipoprotein(a) and calcific aortic valve disease: current evidence and future directions. Curr Opin Clin Nutr Metab Care. 2024;27:77\u201386.","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"1365_CR75","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1194\/jlr.M012526","volume":"52","author":"S Lamon-Fava","year":"2011","unstructured":"Lamon-Fava S, Marcovina SM, Albers JJ, et al. Lipoprotein(a) levels, apo(a) isoform size, and coronary heart disease risk in the Framingham offspring study. J Lipid Res. 2011;52:1181\u20137.","journal-title":"J Lipid Res"},{"key":"1365_CR76","doi-asserted-by":"publisher","unstructured":"Vinci P, Di Girolamo FG, Panizon E, et al. Lipoprotein(a) as a risk factor for cardiovascular diseases: pathophysiology and treatment perspectives. Int J Environ Res Public Health. 2023. https:\/\/doi.org\/10.3390\/ijerph20186721.","DOI":"10.3390\/ijerph20186721"},{"key":"1365_CR77","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1161\/CIRCULATIONAHA.124.069556","volume":"151","author":"HS Bhatia","year":"2025","unstructured":"Bhatia HS, Wandel S, Willeit P, et al. Independence of lipoprotein(a) and low-density lipoprotein cholesterol-mediated cardiovascular risk: a participant-level meta-analysis. Circulation. 2025;151:312\u201321.","journal-title":"Circulation"},{"key":"1365_CR78","doi-asserted-by":"publisher","first-page":"eJAHA2024040361","DOI":"10.1161\/JAHA.124.040361","volume":"14","author":"D Patel","year":"2025","unstructured":"Patel D, Koschinsky ML, Agarwala A, et al. Role of lipoprotein(a) in atherosclerotic cardiovascular disease in South Asian individuals. J Am Heart Assoc. 2025;14:eJAHA2024040361T.","journal-title":"J Am Heart Assoc"},{"key":"1365_CR79","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1161\/ATVBAHA.114.304785","volume":"35","author":"W Guan","year":"2015","unstructured":"Guan W, Cao J, Steffen BT, et al. Race is a key variable in assigning lipoprotein(a) cutoff values for coronary heart disease risk assessment: the Multi-Ethnic study of atherosclerosis. Arterioscler Thromb Vasc Biol. 2015;35:996\u20131001.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1365_CR80","doi-asserted-by":"publisher","first-page":"119218","DOI":"10.1016\/j.atherosclerosis.2025.119218","volume":"406","author":"F Kronenberg","year":"2025","unstructured":"Kronenberg F, Bedlington N, Ademi Z, et al. The Brussels international declaration on Lipoprotein(a) testing and management. Atherosclerosis. 2025;406:119218.","journal-title":"Atherosclerosis"},{"issue":"1","key":"1365_CR81","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL. 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111\u201388.","journal-title":"Eur Heart J"},{"key":"1365_CR82","doi-asserted-by":"publisher","first-page":"e308\u201319","DOI":"10.1016\/j.jacl.2024.03.001","volume":"18","author":"ML Koschinsky","year":"2024","unstructured":"Koschinsky ML, Bajaj A, Boffa MB, et al. A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice. J Clin Lipidol. 2024;18:e308\u201319.","journal-title":"J Clin Lipidol"},{"key":"1365_CR83","doi-asserted-by":"crossref","unstructured":"Grundy SM, Stone NJ, Bailey AL, NLA\/PCNA Guideline on the Management of Blood Cholesterol. 2018 A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73:e285\u2013350. http:\/\/www.AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA.","DOI":"10.1016\/j.jacc.2018.11.003"},{"key":"1365_CR84","first-page":"101826","volume":"4","author":"AC Razavi","year":"2025","unstructured":"Razavi AC, Richardson LC, Coronado F, et al. Prevalence and correlates of lipoprotein(a) testing in a diverse cohort of U.S. adults. JACC: Advances. 2025;4:101826.","journal-title":"JACC: Advances"},{"key":"1365_CR85","doi-asserted-by":"publisher","first-page":"e031255","DOI":"10.1161\/JAHA.123.031255","volume":"12","author":"HS Bhatia","year":"2023","unstructured":"Bhatia HS, Hurst S, Desai P, Zhu W, Yeang C. Lipoprotein(a) testing trends in a large academic health system in the United States. J Am Heart Assoc. 2023;12:e031255.","journal-title":"J Am Heart Assoc"},{"key":"1365_CR86","doi-asserted-by":"publisher","unstructured":"Handelsman Y, Jellinger PS, Guerin CK, et al. Consensus statement by the American association of clinical endocrinologists and American college of endocrinology on the management of dyslipidemia and prevention of cardiovascular disease algorithm \u2013 2020 executive summary. Endocr Pract. 2020. https:\/\/doi.org\/10.4158\/CS-2020-0490.","DOI":"10.4158\/CS-2020-0490"},{"key":"1365_CR87","doi-asserted-by":"publisher","first-page":"e720","DOI":"10.1016\/j.jacl.2024.07.003","volume":"18","author":"M Pavlyha","year":"2024","unstructured":"Pavlyha M, Li Y, Crook S, Anderson BR, Reyes-Soffer G. Race\/ethnicity and socioeconomic status affect the assessment of lipoprotein(a) levels in clinical practice. J Clin Lipidol. 2024;18:e720-8.","journal-title":"J Clin Lipidol"},{"key":"1365_CR88","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1161\/CIR.0000000000001191","volume":"148","author":"SS Khan","year":"2023","unstructured":"Khan SS, Coresh J, Pencina MJ, et al. Novel prediction equations for absolute risk assessment of total cardiovascular disease incorporating cardiovascular-kidney-metabolic health: a scientific statement from the American Heart Association. Circulation. 2023;148:1982\u20132004.","journal-title":"Circulation"},{"key":"1365_CR89","doi-asserted-by":"publisher","first-page":"100940","DOI":"10.1016\/j.jacadv.2024.100940","volume":"3","author":"R Dudum","year":"2024","unstructured":"Dudum R, Huang Q, Yan XS, Fonseca MA, Jose P, Sarraju A, Palaniappan L, Rodriguez F. Lipoprotein(a) levels in disaggregated Racial and ethnic subgroups across atherosclerotic cardiovascular disease risk levels. JACC Adv. 2024;3:100940.","journal-title":"JACC Adv"},{"key":"1365_CR90","doi-asserted-by":"publisher","first-page":"e177","DOI":"10.1016\/j.jacc.2019.03.010","volume":"74","author":"DK Arnett","year":"2019","unstructured":"Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: A report of the American college of Cardiology\/American heart association task force on clinical practice guidelines. J Am Coll Cardiol. 2019;74:e177\u2013232.","journal-title":"J Am Coll Cardiol"},{"key":"1365_CR91","doi-asserted-by":"publisher","unstructured":"Iatan I, Koschinsky ML, Trenaman L, Zhang W, Thanassoulis G, Brunham LR, Mancini GBJ, Francis GA. Rationale for the routine screening of lipoprotein (a) in cardiovascular risk assessment. Eur J Prev Cardiol. 2025. https:\/\/doi.org\/10.1093\/eurjpc\/zwaf342.","DOI":"10.1093\/eurjpc\/zwaf342"},{"key":"1365_CR92","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/dom.16469","volume":"8","author":"AC Razavi","year":"2025","unstructured":"Razavi AC, Bhatia HS, Blumenthal RS, Shapiro MD, Mehta A. Why, how and in whom should we measure levels of lipoprotein(a): A review of the latest evidence and clinical implications. Diabetes Obes Metab 27 Suppl. 2025;8:34\u201346.","journal-title":"Diabetes Obes Metab 27 Suppl"},{"key":"1365_CR93","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jacc.2019.10.057","volume":"75","author":"VA Bittner","year":"2020","unstructured":"Bittner VA, Szarek M, Aylward PE, et al. Effect of Alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome. J Am Coll Cardiol. 2020;75:133\u201344.","journal-title":"J Am Coll Cardiol"},{"key":"1365_CR94","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","volume":"139","author":"ML O\u2019Donoghue","year":"2019","unstructured":"O\u2019Donoghue ML, Fazio S, Giugliano RP, et al. Lipoprotein(a), PCSK9 Inhibition, and cardiovascular risk. Circulation. 2019;139:1483\u201392.","journal-title":"Circulation"},{"key":"1365_CR95","unstructured":"An Update on Lipoprotein(a). The Latest on Testing, Treatment, and Guideline Recommendations. In: American College of Cardiology. https:\/\/www.acc.org\/Latest-in-Cardiology\/Articles\/2023\/09\/19\/10\/54\/An-Update-on-Lipoprotein-a. Accessed 20 Aug 2025."},{"key":"1365_CR96","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1093\/eurjpc\/zwab171","volume":"29","author":"LM de Boer","year":"2022","unstructured":"de Boer LM, Oorthuys AOJ, Wiegman A, Langendam MW, Kroon J, Spijker R, et al. Statin therapy and lipoprotein(a) levels: a systematic review and meta-analysis. Eur J Prev Cardiol. 2022;29:779\u201392.","journal-title":"Eur J Prev Cardiol"},{"key":"1365_CR97","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1161\/ATVBAHA.118.312267","volume":"39","author":"BT Steffen","year":"2019","unstructured":"Steffen BT, Thanassoulis G, Duprez D, Stein JH, Karger AB, Tattersall MC, et al. Race-based differences in lipoprotein(a)-associated risk of carotid atherosclerosis. Arterioscler Thromb Vasc Biol. 2019;39:523\u20139.","journal-title":"Arterioscler Thromb Vasc Biol"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-025-01365-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11883-025-01365-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-025-01365-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T09:02:32Z","timestamp":1763370152000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11883-025-01365-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,17]]},"references-count":97,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1365"],"URL":"https:\/\/doi.org\/10.1007\/s11883-025-01365-0","relation":{},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"value":"1523-3804","type":"print"},{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,17]]},"assertion":[{"value":"29 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No human or animal subjects were used in this review.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights informed consent"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"117"}}